

## Special Issue

# Molecular Biomarkers and Precision Medicine for Pancreatic, Liver and Biliary Tract Cancers

### Message from the Guest Editor

Pancreatic ductal adenocarcinoma (PDAC), liver and biliary tract Cancers (including ampullary cancer, gallbladder cancer, and cholangiocarcinoma) are aggressive malignancies. Most patients present with advanced disease due to late diagnosis, and as there are few effective therapeutic options, outcomes are extremely poor. In this Special Issue, we are inviting original research articles, reviews, and perspectives, to address some of these challenges for these tumours. Topics will include but are not limited to the biology and genomic characteristics of these cancers; the coding and noncoding transcriptome; the role of extracellular vesicles; biomarkers in tissue, blood and biofluids; “liquid biopsies”; the identification of novel therapeutic targets; and new approaches for treating localized and more advanced disease.

---

### Guest Editor

Dr. Adam E. Frampton

Department of Clinical and Experimental Medicine, Faculty of Health ,  
University of Surrey, Guildford GU2 7WG, UK

---

### Deadline for manuscript submissions

closed (31 October 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/33043](https://mdpi.com/si/33043)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)